Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

BACKGROUND: Triple negative breast cancer (TNBC) represents 15–20% of breast cancers. Due to its heterogeneity and high rates of relapse, there is a need to optimize treatment efficacy. Platinum chemotherapy is still controversial and currently not recommended as first-line treatment for TNBC. Recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandy, Jessa Gilda P., Balolong-Garcia, Joanmarie C., Cruz-Ordinario, Mel Valerie B., Que, Frances Victoria F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839096/
https://www.ncbi.nlm.nih.gov/pubmed/31703646
http://dx.doi.org/10.1186/s12885-019-6253-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839096/
https://www.ncbi.nlm.nih.gov/pubmed/31703646
http://dx.doi.org/10.1186/s12885-019-6253-5

Ejemplares similares